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Gaucher disease is caused by inherited deficiency of lysosomal glucocere-
brosidase. Proteome analysis of laser-dissected splenic Gaucher cells
revealed increased amounts of glycoprotein nonmetastatic melanoma pro-
tein B (gpNMB). Plasma gpNMB was also elevated, correlating with chi-
totriosidase and CCL18, which are established markers for human
Gaucher cells. In Gaucher mice, gpNMB is also produced by Gaucher
cells. Correction of glucocerebrosidase deficiency in mice by gene transfer
or pharmacological substrate reduction reverses gpNMB abnormalities. In
conclusion, gpNMB acts as a marker for glucosylceramide-laden macro-
phages in man and mouse and gpNMB should be considered as candidate
biomarker for Gaucher disease in treatment monitoring.
The common lysosomal storage disorder Gaucher dis-
ease (GD) is an autosomal recessively inherited defi-
ciency of lysosomal glucocerebrosidase (GBA; EC
3.2.1.45). GD is clinically heterogeneous, ranging from
the most common non-neuronopathic variant (type 1)
to more severe manifestations involving the central
nervous system and skin [1]. Common to all GD
variants is accumulation of glucosylceramide in lyso-
somes of tissue macrophages causing their transforma-
tion to characteristic lipid-laden Gaucher cells [1].
Progressive accumulation of Gaucher cells in several
organs like spleen, liver, bone marrow, and lung is
thought to lead to the spectrum of visceral symptoms
such as hepatosplenomegaly, pancytopenia, and bone
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disease [1]. Monitoring of factors released by Gaucher
cells in blood allows detection of actual progression of
storage cell formation in patients, a highly variable
process that is not predicted well by the GBA geno-
type as most clearly illustrated by discordant pheno-
types in monozygotic GD twins [2–4]. In addition,
plasma markers of Gaucher cells also offer guidance
for decisions on initiation of therapy and individual-
ized dosing regimens [5]. We previously discovered that
Gaucher cells massively secrete chitotriosidase, an
around 1000-fold elevated enzyme in plasma of symp-
tomatic type 1 GD patients [6]. As sensitive biomarker
of Gaucher cells, it is currently used for diagnosis,
early disease onset, and therapeutic efficacy monitoring
[2,6,7]. Chitotriosidase does not reflect one particular
clinical symptom, but rather the total body burden of
Gaucher cells [7]. Its use as a marker is hampered by
the fact that about 5% to 6% of individuals, including
GD patients, are deficient in chitotriosidase activity
[8]. These individuals cannot be monitored via chi-
totriosidase activity. Other common polymorphisms in
chitotriosidase affecting substrate affinity, limit inter-
pretation of data [9]. The chemokine CCL18, also
named PARC, is overexpressed by Gaucher cells as
well. In plasma and urine of symptomatic GD
patients, several 10-fold elevations exist offering a
good alternative to monitor storage cells [10–12].
Recently, mouse models representing type 1 GD
pathology have been generated using inducible defi-
ciency in GBA in the white blood cell lineage [13,14].
The characteristic lipid-laden macrophages develop in
spleen, liver and bone marrow, recapitulating the
human disease. The promoter of the mouse chitotriosi-
dase gene is fundamentally different not driving
phagocyte-specific expression [15], while the CCL18
gene is entirely absent in the mouse genome [16].
To identify additional surrogate markers of Gaucher
cells in man and mouse, we investigated the proteome
of laser-dissected storage cells from spleen of a type 1
GD patient. gpNMB was prominently detected, is
expressed in macrophages, can be released as a soluble
fragment upon lysosomal stress, has earlier been con-
nected to the disease, and very recently increased levels
were reported in cerebrospinal fluid of the neuropathic
form of GD [7,17,18]. Hence, we investigated gpNMB
in detail. First, soluble gpNMB is markedly increased
in plasma of symptomatic type 1 GD patients. Second,
gpNMB correlates with chitotriosidase and CCL18 in
plasma, prior and during therapy. Finally, GBA-defi-
cient mice developing lipid-laden macrophages also
show increased gpNMB in tissues and circulation. In
conclusion, gpNMB has potential value as a surrogate
marker for GD in man and mouse models.
Materials and methods
Patients
All 59 type 1 Gaucher patients studied (30 males and 29
females) were known by referral to the Academic Medical
Center. The type I Gaucher disease patients studied were
15–64 years old at the initiation of therapy (t = 0). gpNMB
levels were analyzed prior to and 1 year after initiation of
enzyme replacement therapy. Diagnosis was confirmed by
demonstration of markedly reduced glucocerebrosidase
activity and mutant GBA genotype. The controls consisted
of 10 male and 10 female healthy volunteers. Plasma sam-
ples were collected prior to the start of enzyme replacement
therapy. Approval was obtained from the Ethics Commit-
tee of the Academic Medical Center, Amsterdam. Informed
consent was provided according to the Declaration of
Helsinki.
Mouse materials
The generation of the GD1 mouse model (Gbatm1Karl/
tm1KarlTg(Mx1-cre)1Cgn/0) with inducible knock down of
GBA in the white blood cell lineage has been described pre-
viously [13]. Materials, kindly provided by Karlsson (Lund),
were analyzed previously for other biochemical parameters
[19]. Scarb2/ mice deficient in LIMP2 were kindly pro-
vided by Saftig (Kiel) [20]. The mice were housed at the
Academic Medical Center Institute Animal Core Facility in
a temperature- and humidity-controlled room with a 12-h
light/dark cycle and given free access to food and water
ad libitum. All animal protocols were approved by the Insti-
tutional Animal Welfare Committee of the Academic Medi-
cal Centre Amsterdam in the Netherlands. Mice were
sacrificed according to protocol, being first anesthetized
with a dose of Hypnorm (0.315 mgmL1 phenyl citrate and
10 mgmL1 fluanisone) and Dormicum (5 mgmL1 mida-
zolam) according to their weight. The administered dose
was 80 lL per 10 g body weight. Anesthetized animals were
sacrificed by cervical dislocation. Organs were collected by
surgery and rinsed with PBS. All samples and tissues
collected were stored at 80 °C prior to further analysis.
Macrophages
Monocytes were cultured for up to 10 days in RPMI 1640
(BioWhittaker, Viviers, Belgium) supplemented with 10%
human serum (BioWhittaker). Phenotypical maturation was
confirmed by light microscopy. RIPA (150 mmolL1
NaCl, 50 mmolL1 Tris-HCl pH 7.4, 2 mmolL1 EDTA,
0.5% deoxycholaat, 1 mmolL1 Na3VO4, 20 mmolL1
NaF, and 0.5% Triton X-100) supplemented with protease
inhibitor cocktail (Roche, Almere, the Netherlands) and
PMSF lysates were prepared directly after isolation and
after 1, 3, 5, 7, and 10 days of culture.
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Enzyme activity assays
The enzymatic activity assay for chitotriosidase with 4
MU-deoxychitobiose as substrate was performed at pH 5.2,
as described previously [21].
Glucosylsphingosine measurement
The glycosphingoid base glucosylsphingosine was measured
as described earlier [19].
ELISA and western blot
Plasma gpNMB levels were measured using commercially
available ELISAs as described by the manufacturer (R&D
systems, Abingdon, UK). Western blotting of gpNMB was
performed using commercial mouse anti-gpNMB antibody
(MAB25501; R&D systems). Plasma CCL18 concentrations
were determined by ELISA exactly as described earlier [10].
RNA isolation, northern blot, and qPCR
Total spleen RNA of a type 1 patient was isolated using
the RNAzol B (Biosolve, Barneveld, The Netherlands)
RNA isolation kit according to the manufacturer’s instruc-
tions. For Northern blot analysis, 15-lg samples of total
RNA were run in 10 mM HEPES (N-2-hydroxyethylpipera-
zine-N’-2-ethanesulfonic acid), 6% formaldehyde-agarose
gels, transferred to Hybond N nylon membranes (Amer-
sham, Buckinghamshire, UK) by the capillary method, and
immobilized by UV cross-linking. The following probes
were used: full-length gpNMB cDNA and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) as an RNA control.
The probes were radiolabeled with 32P using the random
priming method. qPCR was performed using human
gpNMB forward primers 50-gggtctgggacgtactgtgt-30and
reverse primers 50-ctcaggcctttgcttctgac-30. Expression levels
were normalized to those of acidic ribosomal phosphopro-
tein 36B4, also referred to as P0. Forward 50-tcgacaatggcag-
catctac-30 and reverse 50-atccgtctccacagacaagg-30.
Immunohistochemistry
Immunohistochemistry was performed on frozen sections
of a type 1 GD spleen to detect expression patterns of
gpNMB using an earlier described methodology [22]. In
brief, frozen sections of 6 lm were cut and thaw-mounted
on glass slides. Slides were kept overnight at RT in humidi-
fied atmosphere. After air-drying the slides for 1 h, slides
were fixed in fresh acetone containing 0.02% (vol/vol)
H2O2. Slides were then air-dried for 10 min, washed with
phosphate-buffered saline (PBS), and incubated with opti-
mally diluted mouse antihuman gpNMB monoclonal anti-
body (MAB25501; R&D systems) overnight at 4 °C in a
humidified atmosphere. Incubations with secondary rabbit
anti-mouse-Ig-biotin (Dako, Glostrup, Denmark) and ter-
tiary HRP-labeled avidin-biotin-complex (ABC/HRP;
Dako) were performed for 1 h at RT. Between incubation
steps, slides were washed twice with PBS. HRP activity was
revealed by incubation for 10 min at RT with 3-amino-9-
ethyl-carbazole (AEC; Sigma, Zwijndrecht, the Nether-
lands), leading to a bright red precipitate. After washing,
sections were counterstained with hematoxylin and embed-
ded with glycerol-gelatin. Primary antibody reagent omis-
sion control staining was performed.
Laser microdissection of Gaucher cells
From frozen spleen of a type 1 patient stored at 80 °C,
10-lm cryostat sections were prepared. One section was
stained with hematoxylin and examined microscopically in
order to detect tissue areas of interest for microdissection.
Corresponding consecutive tissue sections were mounted on
a microscope slide coated with a membrane [polyethylene
naphthalate (PEN) Zeiss/Palm, Bernried, Germany] and
stored at 80 °C. Comparison of stained and unstained tis-
sue sections revealed that hematoxylin staining had no
influence on the quantitative protein measurements and
identification using LC-MSe. Tissue areas were cut using a
VeritasTM Microdissection System (Arcturus Molecular
Devices, CA, USA), as described earlier [23]. Slides were
stained for 1 min with hematoxylin. The dissected tissue
samples contained at least 90% macrophages based on
microscopic examination, a few hundred cells from each
sample.
Proteome analysis
Cells were denatured in 20 lL 0.1% RapiGest detergent
solution (Waters Corp., Milford, MA, USA) and heated at
80 °C for 15 minutes. After centrifugation at 1750 g for
10 min, the supernatants were collected. Several tests were
performed to determine the optimal lysis conditions. In addi-
tion, a small piece of frozen Gaucher or control spleen was
homogenized in 30 lL water (HPLC-grade, Biosolve, The
Netherlands) and debris was removed by centrifugation. The
protein concentration of the different homogenates was
determined by bicinchoninic acid-assay according to the
manufacturer’s protocol (Thermo-scientific, Landsmeer,
the Netherlands). Subsequently, Rapigest SF was added to
the whole-spleen homogenates to a final concentration of
0.1% and ammonium bicarbonate to all homogenates to a
final concentration of 50 mM. Protein disulfide bridges were
reduced and alkylated by subsequent incubation with
10 mM dithiothreitol and 25 mM iodoaceteamide. Tryptic
digestion was initiated by the addition of trypsin (gold mass
spectrometry grade, Promega, Leiden, the Netherlands) in a
ratio by weight of 1:100 (protease: protein) and overnight
incubation at 37 °C. Following digestion, breakdown of the
acid-labile Rapigest SF was achieved by addition of
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trifluoroacetic acid according to the manufacturer’s proto-
col. The protein composition was analyzed by LC-MSE, a
mass spectrometric procedure allowing identification and
quantification of proteins without the need of labeling [24].
For this purpose, samples were centrifuged for 10 min at
14000 g and ~0.5 lg was loaded onto a NanoAcquity system
(Waters Corporation) equipped with a Bridged Ethyl Hybrid
C18 1.7 lm, 15-cm 9 150-lm analytical reversed phase col-
umn (Waters Corporation), and operated at a column flow
rate of 1 lLmin1 and separated by gradient conditions as
described before [24]. Analysis of tryptic peptides was per-
formed using a Synapt MS mass spectrometer (Waters Cor-
poration, Manchester, UK) with the operating and
experimental conditions as previously described [24]. Accu-
rate mass precursor and fragment ion LC-MS data were col-
lected in data-independent LC-MSE mode of acquisition
[25,26]. Continuum LC-MS data were processed and
searched using Protein Lynx Global SERVER version 2.3
(Waters Corporation) with search parameters as described
before [24]. Briefly, tryptic cleavage rules were applied,
allowing for 1 missed cleavage, in addition, carbo-
midomethylation was set as fixed modification of cysteine
residues while methionine oxidation was set as variable mod-
ification. Protein identifications were obtained searching the
human SwissProt entries of a UniProt database (release
13.2) that was modified to include N-terminal processing of
proteins using the protein maturation device software [27]
while estimations of false positive rates of protein identifica-
tions were obtained by simultaneous searches in a reversed
version of the same database generated by ProteinLynx Glo-
balSERVER. Absolute amounts (ng) of proteins were esti-
mated using the combined intensity of the 3 best ionizing
peptides and the universal response factor of the mass spec-
trometer supplied by the manufacturer [28]. Data were
exported as a csv-file for further analysis. Robust criteria
were applied for quantification: patient and control samples
were run in triplicate and only proteins that were identified
in more than one run were reported. False-positive identifi-
cation rates per protein were calculated taking into account
the criteria mentioned above and were ~0.38%. In order to
normalize for differences in protein concentration between
samples loaded, each run was normalized on total protein
amount based on the bicinchoninic acid-assay performed on
each homogenate. The resulting value reported is ng of pro-
tein per lg of total protein (nglg1). Proteins that were only
identified in either Gaucher or control samples were required
to be detected in all three replicate runs, and to be at least 10
times above the signal intensity of the least abundant protein
detected in order to be reported.
Statistical analysis
Correlations were tested by the rank correlation test
(Spearman coefficient, rho). P values < 0.05 were consid-
ered statistically significant.
Results
Proteomics of Gaucher cells in GD spleen
To identify novel factors released by Gaucher cells in
plasma, we first investigated the protein composition
of these cells by mass spectrometry. Lipid-laden stor-
age cells were isolated from a section of spleen from a
type 1 GD patient by means of laser-dissection
(Fig. 1A). The protein composition of the homogenate
of pooled sections (n = 6), representing approximately
2000 storage cells, was analyzed by LC-MSE and com-
pared to a similar-sized fraction of normal spleen. Fig-
ure 1B shows that some proteins were highly abundant
in storage cell preparations. Most striking in this
respect were prosaposin, cathepsin D, and gpNMB.
Similar results were obtained following LC-MSE analy-
sis of total homogenates of GD and control spleens
(Fig. S1).
Elevated gpNMB in GD spleen
Previous subtractive hybridization studies on GD
spleen [11] and microarray analysis (J.M. Aerts,
unpublished findings) already pointed to increased
expression of gpNMB in type 1 GD spleens. In addi-
tion, it has been documented that gpNMB can be shed
as a soluble factor [17]. The highly increased presence
of gpNMB RNA in type 1 GD spleen was demon-
strated by Northern blot and qPCR (Fig. 2A). Next,
we investigated gpNMB at the protein level. Western
blot analysis using an anti-human gpNMB mouse
monoclonal antibody confirmed the proteomics find-
ings (Fig. 2B). In a homogenate of GD spleen, but not
that of control tissue, gpNMB was detected. A similar
observation was made for chitotriosidase (Fig. 2B).
Consistent with high expression of gpNMB in Gaucher
cells, we observed expression in human monocyte-
derived macrophages (Fig. 2C). Immunohistochemistry
on sections from spleens of a type 1 GD patient
unequivocally revealed the specific expression of
gpNMB protein in Gaucher cells (Fig. 2D). Expression
of gpNMB was virtually absent in other cells in this
spleen section.
Elevated gpNMB in GD plasma
Since gpNMB can be proteolytically shed from cells,
the occurrence of soluble fragments in the circulation
was examined. Western blot analysis of plasma
(0.5 lL) of type 1 GD patients using anti-human
gpNMB antiserum revealed the presence of gpNMB,
but not in the case of plasma of normal subjects
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Fig. 1. Proteomics of laser-dissected
Gaucher cells. (A) Laser-dissection of
Gaucher cells from type 1 GD spleen. (B)
LC-MSE of isolated Gaucher cells.
Fig. 2. Increased gpNMB in GD spleen.
(A) Left panel: northern blot for gpNMB
RNA in type 1 GD and control spleen.
Right panel: qPCR of gpNMB mRNA in
type 1 GD and normal spleen. (B) Western
blot detection of gpNMB and
chitotriosidase in type 1 GD and control
spleen. (C) Western blot detection of
gpNMB in human monocyte-derived
macrophages (from left to right marker,
monocytes and 1, 3, 5, 7, or, 10 days
matured macrophages). (D)
Immunohistochemical detection of gpNMB
in Gaucher cells in type 1 GD spleen using
a mouse monoclonal antibody.
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(Fig. 3A). To quantify the levels of gpNMB, a sand-
wich ELISA was used. Figure 3B shows that plasma
gpNMB levels were clearly increased (on average 25-
fold) in all tested 59 symptomatic type 1 GD patients
(plasma taken prior to initiation of therapy). The
mean plasma gpNMB level in controls is 20 ngmL1
(range, 11–34 ngmL1), whereas that in patients’ sam-
ples was 495 ngmL1 (range, 137–1283 ngmL1). No
overlap was seen between values in the examined
patients and controls. Interestingly, elevated circula-
tory levels of gpNMB were also observed in three of
four type 2/type 3 patients sera analyzed.
The relationship between gpNMB and glucosylce-
ramide and gpNMB and glucosylsphingosine was first
determined. Plasma gpNMB correlated with glucosyl-
ceramide (q = 0.036; P = 0.015) and better with gluco-
sylsphingosine (q = 0.46; P = 0.0007) (Fig. 3C,D). The
relationship between gpNMB and two other estab-
lished Gaucher cell markers, chitotriosidase and
CCL18, in plasma of type 1 GD patients was further
examined. Plasma gpNMB levels in untreated GD
patients correlated well with those of chitotriosidase
(q = 0.41; P < 0.05) and CCL18 (q = 0.40; P < 0.05)
(Fig. 3E,F). A similar correlation was found with total
b-hexosaminidase activity in plasma specimen
(q = 0.40; P < 0.05) (Fig. S2). The correlation of chi-
totriosidase and CCL18 in the same samples was bet-
ter (q = 0.69; P < 0.05) (data not shown). No
correlation between plasma gpNMB levels and disease
severity was observed.
Corrections in plasma gpNMB in GD patients
receiving therapy
Enzyme replacement therapy (ERT) of type 1 GD
patients results in prominent reductions of Gaucher
cells in tissues, reflected by corrections in plasma chi-
totriosidase levels [5]. We investigated the effect of
ERT on plasma gpNMB of type 1 GD patients
(Fig. 4). Western blot analysis of plasma samples col-
lected from patients during therapy already revealed a
prominent reduction in gpNMB protein (Fig. 4A).
Quantification of plasma gpNMB by ELISA in sam-
ples collected at start of ERT and after 1 year treat-
ment (range 10–14 months) showed major correction
in plasma gpNMB with treatment in nearly every
Fig. 3. Plasma gpNMB in type 1 GD
patients. (A) Western blot detection of
gpNMB in 0.5 lL type 1 GD and control
plasma. (B) ELISA quantification of
gpNMB in type 1 GD (squares) and control
plasma (circles). (C) Correlation of plasma
gpNMB and glucosylceramide (GlcCer). (D)
Correlation of plasma gpNMB and
glucosylsphingosine (Glc-Spho). (E)
Correlation of plasma gpNMB and
chitotriosidase. (F) Correlation of plasma
gpNMB and CCL18.
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patient (Fig. 4B and Table S1). We next compared the
corrections in plasma gpNMB with those in chi-
totriosidase (value at start of ERT being 100%). A
very strong correlation was observed in relative correc-
tions of gpNMB and chitotriosidase (Fig. 4C). The
two most striking responders for gpNMB (84% and
92% reduction) also showed concomitantly a striking
reduction in chitotriosidase (both cases 85%), indicat-
ing an impressive reduction in Gaucher cells.
gpNMB in GD mice
Next, we examined gpNMB in type 1 GD mice with
inducible knock down of glucocerebrosidase in the
hematopoietic lineage by polyinosinic-polycytidylic
acid treatment (Gbatm1Karl/tm1Karl) (Fig. 5). These ani-
mals develop characteristic Gaucher cells for instance
found in spleen and liver when expression of gluco-
cerebrosidase is down-regulated [19]. The level of
gpNMB is markedly increased in plasma of the GD
mice (Fig. 5A). The effect of therapeutic interventions
on plasma gpNMB was subsequently investigated. We
first studied the impact of substrate reduction (SRT)
as accomplished by administration of eliglustat, a
potent inhibitor of the synthesis of glucosylceramide
by GCS and recently registered by the FDA for the
treatment of type 1 GD [29,30]. In SRT-treated type 1
GD mice (Gbatm1Karl/tm1Karl) plasma gpNMB was
Fig. 4. Correction of elevated plasma
gpNMB by enzyme replacement therapy.
(A) ERT-induced reduction of plasma
gpNMB (western blot). (B) ERT-induced
reductions of plasma gpNMB (ELISA). (C)
Correlation of relative change in excess
plasma gpNMB and chitotriosidase.
Fig. 5. Elevated gpNMB in GD mice. (A)
Increased plasma gpNMB in GD mice and
effect of substrate reduction therapy using
Eliglustat (GENZ) in GD mice (left panel).
Data are depicted as mean  SEM.
Correlation of plasma glucosylsphingosine
and gpNMB in GD and Eliglustat treated
mice (right panel). (B) Effect of GBA gene
therapy on gpNMB in mice on liver,
spleen, and bone marrow. PGK control
indicates treatment with self-inactivating
lentiviral vectors without the GBA gene
under the control of human
phosphoglycerate kinase (PGK); PCK
GBA1: same vector with GBA gene; SFFV
GBA1: vector with constitutive SFFV
promotor and GBA gene; GD untreated
animals; WT: matched normal animals
(see ref. 19). Data are depicted as
mean  SEM. n = 3 per group.
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reduced (Fig. 5A). The reduction in plasma gpNMB
correlated with that of glucosylsphingosine, a measure
for the presence of lipid-laden macrophages [31–33]
(Fig. 5A). Next, we examined the effect of treatment
of diseased Gbatm1Karl/tm1Karl mice through gene ther-
apy with self-inactivating lentiviral vectors with the
GBA gene under the control of human phosphoglycer-
ate kinase (PGK) as reported previously [19]. Mice
which were functionally corrected in GBA, showed a
reduction of gpNMB in liver, spleen, and bone mar-
row (Fig. 5B).
Mice with a genetic loss of SCARB2 lacking the
membrane protein LIMP2 that transports GBA to
lysosomes show marked GBA deficiency in most tis-
sues and cell types, except white blood cells. The Scar-
b2/ mice, like LIMP2 deficient patients, suffer from
action myoclonus renal failure syndrome, but do not
develop lipid-laden macrophages as in GD [34,35]. We
could not detect abnormalities in gpNMB in LIMP2-
deficient mice (see Fig. S3). This finding illustrates the
need of lysosomal stress, hence lysosomal lipid accu-
mulation causing lysosomal perturbations, in macro-
phages for gpNMB overexpression, and its release in
the circulation. In conclusion, our findings indicate
that gpNMB may serve as a sensitive marker for for-
mation of lipid-laden cells in GD mouse models.
Discussion
This study extends our earlier observation of abnor-
malities in gpNMB in GD patients [7,11] toward iden-
tification of a candidate biomarker for therapy
monitoring. We here describe that in a cohort of
symptomatic type 1 GD patients, plasma gpNMB is
commonly and markedly increased. We show that
gpNMB is produced by lipid-laden macrophages, Gau-
cher cells, in tissues of GD patients. gpNMB levels
correlate strongly with those of validated Gaucher cell
markers such as chitotriosidase and glucosylsphingo-
sine. Changes in Gaucher cell markers in GD patients
receiving therapy are accompanied by comparable cor-
rections in gpNMB. Finally, immunohistochemistry of
spleen and data for laser-dissected Gaucher cells con-
firm overexpression of gpNMB by Gaucher cells. Con-
sistent with our finding, Futerman and colleagues
reported very recently elevated levels of gpNMB in
cerebrospinal fluid of neuronopathic GD patients as
well as neuronopathic GD mice [18]. They proposed
that gpNMB may serve as a marker to quantify neu-
ropathology. Of note, activated microglia, the CNS
functional counterpart of macrophages, recently have
been reported to express gpNMB [36]. gpNMB plasma
levels are also strongly elevated in mouse models of
Niemann–Pick type C (NPC) disease and to a lesser
degree in NPC patients. NPC-macrophages generated
using the drug U18666A also induced Gpnmb and gly-
cosphingolipid synthesis inhibition prevented this [37].
gpNMB is expressed by phagocytic cell types like
macrophages, dendritic cells, and osteoclasts as well as
melanocytes [17]. It has also been documented earlier
that breast cancer cells release soluble fragments
through active shedding, presumably by the action of
the membrane-bound protease ADAM10 [38]. We
recently reported that gpNMB expression in macro-
phages is under the control of the transcription factor
MITF and is markedly increased upon lysosomal
stress [39]. Increased GPNMB mRNA was noted pre-
viously for type 1 GD spleen [11] and for liver of mice
with induced GBA deficiency in hematopoietic and
mesenchymal cells [14]. All in all, the here documented
marked increase in circulating gpNMB in type 1 GD
patients now fully documented here is entirely consis-
tent with previous more scattered findings.
Given the marked abnormality in gpNMB in type 1
GD patients, recent insights in the function of this
protein warrant discussion. In the previous years, the
protein gpNMB, also named osteoactivin or DC-HIL
(DC-associated heparan sulfate proteoglycan-depen-
dent integrin ligand), received considerable attention in
different research fields. A number of investigators
have focused on its role in bone metabolism. The
expression of gpNMB in osteoclasts has been docu-
mented for some time, but in addition, very recent
studies point to a crucial role of osteoactivin in bone
formation as indicated by the negative consequences of
deficiency of the protein for bone generation [40–42].
It is of interest to note that impaired bone formation
is presently considered an important contributor to the
complex skeletal abnormalities observed in type 1 GD
patients [14,43]. Our findings might therefore stimulate
further investigations on the potential role of this pro-
tein in skeletal GD disease.
The protein gpNMB has also drawn attention of
researchers studying the interaction of dendritic cells
(DC) and T cells. gpNMB is expressed by dendritic
cells critically regulated by the transcription factor
MITF [44]. gpNMB on antigen presenting cells inhi-
bits T-cell activation by binding to syndecan-4 (SD-4)
on T cells [45,46]. It has been hypothesized that the
DC-HIL/SD-4 pathway regulates autoimmune
responses. Investigations on experimental autoimmune
encephalomyelitis (EAE) as a model for multiple scle-
rosis indeed have rendered evidence that the DC-HIL/
SD-4 pathway regulates autoimmune responses by
mediating the T-cell suppressor function of CD11b(+)
Gr-1(+) myeloid-derived suppressor cells (MDSC) [47].
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Of note, a genome-wide association meta-analysis of
12 386 Parkinson disease (PD) cases and 21 026 con-
trols led to the identification of PD risk loci, including
gpNMB (7p15) [48,49]. Also from functional studies,
in recent years, it has become apparent that also muta-
tions in GBA, the primary defect in GD, constitute a
risk for developing PD [50].
Beyond its tentative (patho)physiological functions,
gpNMB is of interest as a potential marker for lipid-
laden macrophages in type 1 GD. Immunohistochemi-
cal analysis of type 1 GD spleen sections demonstrates
that Gaucher cells are a prominent source of gpNMB.
The close correlation of plasma gpNMB with two
established markers of Gaucher cells, chitotriosidase
and CCL18, suggests that it reflects the body burden
of Gaucher cells. Additional markers of Gaucher cells
are still of value: the validated biomarker chitotriosi-
dase cannot be used in every individual due to gene
mutations [7]. The plasma concentration of chemokine
CCL18 is close to normal in mildly affected type 1
GD patients. In our view, plasma gpNMB can serve
as additional GD marker for further confirmation of
diagnosis, and monitoring of disease progression or
correction following therapeutic intervention. We
already noted that fractional corrections in plasma
gpNMB and chitotriosidase are similar in type 1 GD
patients during therapy. Of note, plasma gpNMB, like
chitotriosidase and CCL18, does not reflect one partic-
ular clinical manifestation of type 1 GD. We like to
stress that measurement of the plasma gpNMB for pri-
mary diagnosis of GD should not be advocated.
Increased expression has been also noted in other dis-
ease conditions, as for example, illustrated by the
recent report on atherosclerosis [51]. Only in cases
where GD has been demonstrated by GBA deficiency
and gene defects, monitoring of plasma gpNMB level
is useful.
Our investigation further revealed that also in mice,
gpNMB is excessively produced and released by gluco-
sylceramide-laden macrophages with deficient GBA
activity. Vice versa, gpNMB abnormalities are reduced
by correction of the GBA deficiency or prevention of
lysosomal glucosylceramide accumulation. Since chi-
totriosidase and CCL18 cannot be used as biomarkers
of Gaucher cells in mice, gpNMB offers a very attrac-
tive alternative in this respect. Fundamental investiga-
tions on pathophysiology and therapy in GD mouse
models may profit from determination of gpNMB as
biomarker for Gaucher cells.
In conclusion, our finding of markedly elevated
plasma gpNMB levels in symptomatic Gaucher
patients warrants further investigations regarding its
applicability in the clinical management of Gaucher
disease as well as its role in the peculiar pathophysiol-
ogy of the disorder.
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